

**Anti-RSPO3 Reference Antibody (rosmantuzumab)**  
**Recombinant Antibody**  
**Catalog # APR10411**

**Specification**

**Anti-RSPO3 Reference Antibody (rosmantuzumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">Q9BXY4</a>
Reactivity	Cynomolgus, Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

**Anti-RSPO3 Reference Antibody (rosmantuzumab) - Additional Information**

**Target/Specificity**  
RSPO3

**Endotoxin**  
< 0.001EU/ µg, determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Anti-RSPO3 Reference Antibody (rosmantuzumab) - Protein Information**

**Name** RSPO3

**Synonyms** PWTSR, THSD2

**Function**

Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors, which acts as a key regulator of angiogenesis. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway (PubMed:<a href="http://www.uniprot.org/citations/21727895" target="\_blank">21727895</a>, PubMed:<a href="http://www.uniprot.org/citations/21909076" target="\_blank">21909076</a>, PubMed:<a href="http://www.uniprot.org/citations/22615920" target="\_blank">22615920</a>).

Acts as a key regulator of angiogenesis by controlling vascular stability and pruning: acts by activating the non-canonical Wnt signaling pathway in endothelial cells (By similarity) (PubMed:<a href="http://www.uniprot.org/citations/21727895" target="\_blank">21727895</a>, PubMed:<a href="http://www.uniprot.org/citations/21909076" target="\_blank">21909076</a>, PubMed:<a href="http://www.uniprot.org/citations/22615920" target="\_blank">22615920</a>). Can also amplify Wnt signaling pathway independently of LGR4-6 receptors, possibly by acting as a direct antagonistic ligand to RNF43 and ZNRF3 (PubMed:<a href="http://www.uniprot.org/citations/29769720" target="\_blank">29769720</a>).

**Cellular Location**

Secreted {ECO:0000250|UniProtKB:Q2TJ95}.


**Tissue Location**

Ubiquitously expressed. Expressed at higher level in placenta, small intestine, fetal thymus and lymph node (PubMed:12463421). Highly expressed in endothelial cells (PubMed:26766444).


**Anti-RSPO3 Reference Antibody (rosmantuzumab) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Anti-RSPO3 Reference Antibody (rosmantuzumab) - Images**

Anti-RSPO3 Reference Antibody (rosmantuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-RSPO3 Reference Antibody (rosmantuzumab) is more than 100% ,determined by SEC-HPLC.